Clinical trial BOSTON
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
| Cancers | |
|---|---|
| Organ | Myeloma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Karyopharm |
| EudraCT Identifier | 2016-003957-14 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03110562 |
| Inclusion criteria | - Histologically confirmed MM with measurable disease per IMWG guidelines - Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens |
| Last update |